Dyne Therapeutics, Inc.
DYN
$13.51
$0.9257.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -412.89M | -367.13M | -317.42M | -294.51M | -257.60M |
| Total Depreciation and Amortization | 1.89M | 1.79M | 1.67M | 1.62M | 1.62M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 40.30M | 35.88M | 42.87M | 38.73M | 35.53M |
| Change in Net Operating Assets | 11.13M | 9.74M | -19.49M | 11.12M | 1.44M |
| Cash from Operations | -359.56M | -319.73M | -292.37M | -243.04M | -219.01M |
| Capital Expenditure | -2.37M | -3.17M | -2.38M | -1.38M | -1.30M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -24.81M | -19.62M | -201.70M | -160.49M | -128.35M |
| Cash from Investing | -27.18M | -22.78M | -204.08M | -161.87M | -129.65M |
| Total Debt Issued | 98.80M | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 164.86M | 542.75M | 809.90M | 806.41M | 788.85M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 263.66M | 542.75M | 809.90M | 806.41M | 788.85M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -123.08M | 200.24M | 313.45M | 401.50M | 440.19M |